secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001683168-24-003777
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M
-------------------------------------------------------------------------------

- Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
- Net loss of $(1,283,801) improved from $(1,702,430) in the prior-year quarter.
- Gross profit rose to $2,354,337 from $1,828,122, driven by new product launches.
- In February 2024, completed public offering for gross proceeds of ~$10 million.
- Growth attributed to expanded sales efforts by subsidiary Nora Pharma Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/0001683168-24-003777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer